Renal Business Today - Kidney Patients

WellBound, Arnett Clinic to partner in new center

MOUNTAIN VIEW, Calif.--Wellbound said today it has signed an agreement with an Indiana-based multispecialty clinic to develop a "Center of Excellence" for self-care dialysis therapies. ...More

June 6, 2006

Posted in News, Business, Clinical & Pharma, Practice Management

Renal Advantage to acquire seven Virginia clinics

BRENTWOOD, Tenn.--Renal Advantage Inc. will acquire the assets of seven Virginia dialysis clinics currently owned by Riverside Hospital Inc., according to Renal Advantage. ...More

June 1, 2006

Posted in News, Business, Clinical & Pharma, Practice Management

Vaccinate or Not? Treat or Not? Study Looks at Health Decisions

ANN ARBOR, Mich.--If a deadly bird flu reaches America, which would you choose: To get a risky experimental vaccine now, or to forego that risk but face an even greater risk of dying in the epidemic? What would you choose for your child? What if you were in charge of public ...More

May 31, 2006

Posted in News, Clinical & Pharma, Practice Management

Spectrum recalls kidney transplant drug

GARDENA, Calif.—Spectrum Laboratory Products Inc. has voluntarily recalled all lots of its transplant drug tacrolimus after learning some containers might be less potent than expected, according to a company spokesman. ...More

May 17, 2006

Posted in News, Clinical & Pharma, Government & Regulation, Practice Management

Genzyme says petition against Renagel ‘inaccurate’

CAMBRIDGE, Mass.—A recent petition to the U.S. Food and Drug Administration calling for the withdrawal of Genzyme Corp.’s phosphorus drug Renagel was characterized as “inaccurate” by a Genzyme spokesman Friday. ...More

May 12, 2006

Posted in News, Business, Clinical & Pharma, Government & Regulation, Practice Management

FDA gives Oxford BioMedica study protocol for renal cancer drug

OXFORD, England—The U.S. Food and Drug Administration sent Oxford BioMedica Special Protocol Assessment, which will pave the way for the gene-therapy company to begin phase 3 studies of its renal cell carcinoma drug TroVax ...More

May 12, 2006

Posted in News, Clinical & Pharma, Government & Regulation, Practice Management

Obesity increases risk of chronic renal failure

UPPSALA, Sweden—Obesity greatly increases the risk of chronic renal failure in patients, even for those who do not have diabetes or high blood pressure, according to a study in June’s Journal of the American Society of Nephrology. ...More

May 12, 2006

Posted in News, Clinical & Pharma, Government & Regulation, Practice Management

Doctor calls for withdrawal of Renagel

BOSTON--Dialysis patients using the phosphorus drug Renagel might be at an increased risk of digestive-tract side effects and death, according to a petition filed May 4 to the U.S. Food and Drug Administration by a doctor who has called for the drug’s withdrawal ...More

May 11, 2006

Posted in News, Clinical & Pharma, Government & Regulation, Practice Management

NephroGenex acquires rights to diabetic nephropathy drug

CARY, N.C.—NephroGenex has acquired the commercial rights to the diabetic nephropathy drug Pyridorin after it signed a licensing agreement May 10 with BioStratum Inc. ...More

May 10, 2006

Posted in News, Business, Clinical & Pharma, Practice Management

Gambro to acquire vascular access company

STOCKHOLM—Gambro announced May 9 that it intends to acquire the assets and operations of HemapureAB, a Swedish vascular access company. ...More

May 9, 2006

Posted in News, Business, Clinical & Pharma, Practice Management

Computers & Software	Consulting, Management...
Equipment & Services	Hemodialysis Supplies
Patient Services	More Options...

Kidney Patients

Video Snapshot

Galleries

RBT Poll

Most Popular Articles

Buyer's Guide

Resources

Free Email Updates

featured links

First Name	Last Name
E-Mail